tetano
Editor, Senior Moderator
J Antimicrob Chemother. 2011 Jan 7. [Epub ahead of print]
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
Rodr?guez A, D?az E, Mart?n-Loeches I, Sandiumenge A, Canadell L, D?az JJ, Figueira JC, Marques A, Alvarez-Lerma F, Vall?s J, Balad?n B, Garc?a-L?pez F, Suberviola B, Zaragoza R, Trefler S, Bonastre J, Blanquer J, Rello J; on behalf of the H1N1 SEMICYUC Working Group.
Collaborators (242)
Cobo P, Martins J, Carbayo C, Robles-Musso E, C?rdenas A, Fierro J, Fern?ndez DO, Sierra R, Jes?s Huertos M, Carlos Pozo J, Guerrero R, M?rquez E, Rodr?guez-Carvajal M, Jare?o A, Pomares J, Ballesteros JL, Fern?ndez Y, Lobato F, Prieto JF, Albofedo-S?nchez J, Mart?nez P, D?az Castellanos MA, Sevilla G, Garnacho-Montero J, Hinojosa R, Fern?ndez E, Loza A, Le?n C, Arenzana A, Oca?a D, Navarrete I, Zaheri Beryanaki M, S?nchez I, Avellanas ML, Lander A, Ram?rez de Arellano SG, Marquina Lacueva MI, Luque P, Gonz?lez I, Mont?n JM, Dorado Regil P, Iglesias L, Pascual Gonz?lez C, Quiroga, Garc?a-Rodr?guez A, Socias L, Ib?nez P, Borges-Sa M, Socias A, Del Castillo A, Jord? Marcos R, Bonell JM, Amestar?n I, Ruiz-Santana S, D?az JJ, Sis?n, Hern?ndez D, Trujillo A, Regalado L, Lorente L, Mart?n M, Mart?nez S, C?ceres JJ, Suberviola B, Ugarte P, Garc?a-L?pez F, Alvaro Alonso A, Pasilla A, G?mez Grande ML, Albaya A, Canabal A, Marina L, Sim?n A, Mar?a A??n J, L?pez Messa JB, L?pez Pueyo MJ, Ferreras Z, Macias S, Angel Berezo J, Varela JB, Ojeda AA, Terrero AA, Tena Ezpeleta F, Paez Z, Garc?a A, Catal?n RM, Ferrer M, Torres A, Barbadillo S, Cabr? L, Rovira A, Alvarez-Lerma F, V?zquez A, Nolla J, Fern?ndez F, Cervell? JR, Ma??z R, Ball?s J, Granada RM, Vall?s J, Ort?z M, Gu?a C, Arm?star F, P?ez J, Almirall J, Balanzo X, Rello J, Arnau E, Llopart L, Palomar M, Catal?n I, Sirvent JM, Ferri C, de Arbina NL, Bad?a M, Valverd?-Vidal M, Barcenilla F, Magret M, Esteban MF, Luna J, Nava JM, de Molina JG, Josic Z, Gurri F, Rodr?guez A, Lisboa T, de Mendoza D, Trefler S, Mar?a D?az R, Mesalles E, Jos? JN, Fern?ndez-Zapata A, Recio T, Arrascaeta A, Garc?a-Ramos MJ, Gallego E, Bueno F, D?az M, Cordero ML, Pastor JA, Alvarez-Rocha L, Vila D, Lamas AD, P?rez JB, Ortiz Piquer M, Merayo E, L?pez-Ciudad VJ, Cortez J, Vilaboy E, Saborido EM, Gonz?lez RJ, Freita S, L?pez AM, Canabal J, Ferres E, Monz?n JL, Go?i F, Del Nogal S?ez F, Blasco Navalpotro M, Garc?a-Torrej?n MC, P?rez-Calvo C, L?pez D, Arnaiz L, S?nchez-Alonso S, Velayos C, Del R?o F, Gonz?lez MA, Mart?n MC, Molina JM, Montejo JC, Catal?n M, Albert P, de Pablo A, Guerrero JE, Peyrat JB, Cerd? E, Alvarez M, Pey C, Rodr?guez M, Palencia E, Caballero R, Vaquero C, Mariscal F, Garc?a S, Carrasco N, Prieto I, Li?tor A, Ramos R, Galv?n B, Figueira JC, Soriano MC, Gald?s P, Balandin Moreno B, Del Cabo F, Hermosa C, Gordo F, Algora A, Paredes A, Cambronero JA, G?mez-Rosado S, Prado L?pez LM, Mart?nez S, Abad FF, Mart?nez M, But? SM, Gil Rueda B, Garc?a F, Macaya L, Marav?-Poma E, Jimenez Urra I, Macaya Redin L, Teller?a A, Insansti J, Gonz?lez N, Marco P, Vidaur L, Santamar?a B, Vergara JC, Iruretagoyena Amiano JR, Manzano A, Arenal CC, Olaechea PM, Blanquer J, Reig Valero R, Belenger A, Altaba S, Alvarez-S?nchez B, Alberto Picos S, S?nchez-Miralles A, Bonastre J, Palamo M, Cebrian J, Cu?at J, Romero B, Zaragoza R, Paricio V, Marques A, S?nchez-Morcillo S, Tormo S, Latour J, Angel Garc?a M, Ribas A.
Hospital Joan XXIII, Critical Care Department - IISPV - URV - CIBERES, Tarragona, Spain.
Abstract
Objectives The impact of oseltamivir on mortality in critically ill patients with 2009 pandemic influenza A (2009 H1N1) is not clear. The main objective of this study was to investigate the relationship between the timing of antiviral administration and intensive care unit (ICU) outcomes. Methods Prospective, observational study of a cohort of ICU patients with confirmed 2009 H1N1 infection. Clinical data, treatment and outcome were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 2 days, and patients administered late treatment (LT), initiated after this timepoint. Multivariate analysis and propensity score were used to determine the effect of oseltamivir on ICU mortality. Results Six hundred and fifty-seven patients were enrolled. Four hundred and four (61.5%) patients required mechanical ventilation (MV; mortality 32.6%). Among them, 385 received effective antiviral therapy and were included in the study group. All patients received oseltamivir for a median duration of 10 days (interquartile range 8-14 days). Seventy-nine (20.5%) ET patients were compared with 306 LT patients. The two groups were comparable in terms of main clinical variables. ICU length of stay (22.7 ? 16.7 versus 18.4 ? 14.2 days; P = 0.03), hospital length of stay (34.0 ? 20.3 versus 27.2 ? 18.2 days; P = 0.001) and MV days (17.4 ? 15.2 versus 14.0 ? 12.4; P = 0.04) were higher in the LT group. ICU mortality was also higher in LT (34.3%) than in ET (21.5%; OR = 1.9; 95% CI 1.06-3.41). A multivariate model identified ET (OR = 0.44; 95% CI 0.21-0.87) as an independent variable associated with reduced ICU mortality. These results were confirmed by propensity score analysis (OR = 0.44; 95% CI 0.22-0.90; P < 0.001). Conclusions Our findings suggest that early oseltamivir administration was associated with favourable outcomes among critically ill ventilated patients with 2009 H1N1 virus infection.
PMID: 21385717 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21385717
Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.
Rodr?guez A, D?az E, Mart?n-Loeches I, Sandiumenge A, Canadell L, D?az JJ, Figueira JC, Marques A, Alvarez-Lerma F, Vall?s J, Balad?n B, Garc?a-L?pez F, Suberviola B, Zaragoza R, Trefler S, Bonastre J, Blanquer J, Rello J; on behalf of the H1N1 SEMICYUC Working Group.
Collaborators (242)
Cobo P, Martins J, Carbayo C, Robles-Musso E, C?rdenas A, Fierro J, Fern?ndez DO, Sierra R, Jes?s Huertos M, Carlos Pozo J, Guerrero R, M?rquez E, Rodr?guez-Carvajal M, Jare?o A, Pomares J, Ballesteros JL, Fern?ndez Y, Lobato F, Prieto JF, Albofedo-S?nchez J, Mart?nez P, D?az Castellanos MA, Sevilla G, Garnacho-Montero J, Hinojosa R, Fern?ndez E, Loza A, Le?n C, Arenzana A, Oca?a D, Navarrete I, Zaheri Beryanaki M, S?nchez I, Avellanas ML, Lander A, Ram?rez de Arellano SG, Marquina Lacueva MI, Luque P, Gonz?lez I, Mont?n JM, Dorado Regil P, Iglesias L, Pascual Gonz?lez C, Quiroga, Garc?a-Rodr?guez A, Socias L, Ib?nez P, Borges-Sa M, Socias A, Del Castillo A, Jord? Marcos R, Bonell JM, Amestar?n I, Ruiz-Santana S, D?az JJ, Sis?n, Hern?ndez D, Trujillo A, Regalado L, Lorente L, Mart?n M, Mart?nez S, C?ceres JJ, Suberviola B, Ugarte P, Garc?a-L?pez F, Alvaro Alonso A, Pasilla A, G?mez Grande ML, Albaya A, Canabal A, Marina L, Sim?n A, Mar?a A??n J, L?pez Messa JB, L?pez Pueyo MJ, Ferreras Z, Macias S, Angel Berezo J, Varela JB, Ojeda AA, Terrero AA, Tena Ezpeleta F, Paez Z, Garc?a A, Catal?n RM, Ferrer M, Torres A, Barbadillo S, Cabr? L, Rovira A, Alvarez-Lerma F, V?zquez A, Nolla J, Fern?ndez F, Cervell? JR, Ma??z R, Ball?s J, Granada RM, Vall?s J, Ort?z M, Gu?a C, Arm?star F, P?ez J, Almirall J, Balanzo X, Rello J, Arnau E, Llopart L, Palomar M, Catal?n I, Sirvent JM, Ferri C, de Arbina NL, Bad?a M, Valverd?-Vidal M, Barcenilla F, Magret M, Esteban MF, Luna J, Nava JM, de Molina JG, Josic Z, Gurri F, Rodr?guez A, Lisboa T, de Mendoza D, Trefler S, Mar?a D?az R, Mesalles E, Jos? JN, Fern?ndez-Zapata A, Recio T, Arrascaeta A, Garc?a-Ramos MJ, Gallego E, Bueno F, D?az M, Cordero ML, Pastor JA, Alvarez-Rocha L, Vila D, Lamas AD, P?rez JB, Ortiz Piquer M, Merayo E, L?pez-Ciudad VJ, Cortez J, Vilaboy E, Saborido EM, Gonz?lez RJ, Freita S, L?pez AM, Canabal J, Ferres E, Monz?n JL, Go?i F, Del Nogal S?ez F, Blasco Navalpotro M, Garc?a-Torrej?n MC, P?rez-Calvo C, L?pez D, Arnaiz L, S?nchez-Alonso S, Velayos C, Del R?o F, Gonz?lez MA, Mart?n MC, Molina JM, Montejo JC, Catal?n M, Albert P, de Pablo A, Guerrero JE, Peyrat JB, Cerd? E, Alvarez M, Pey C, Rodr?guez M, Palencia E, Caballero R, Vaquero C, Mariscal F, Garc?a S, Carrasco N, Prieto I, Li?tor A, Ramos R, Galv?n B, Figueira JC, Soriano MC, Gald?s P, Balandin Moreno B, Del Cabo F, Hermosa C, Gordo F, Algora A, Paredes A, Cambronero JA, G?mez-Rosado S, Prado L?pez LM, Mart?nez S, Abad FF, Mart?nez M, But? SM, Gil Rueda B, Garc?a F, Macaya L, Marav?-Poma E, Jimenez Urra I, Macaya Redin L, Teller?a A, Insansti J, Gonz?lez N, Marco P, Vidaur L, Santamar?a B, Vergara JC, Iruretagoyena Amiano JR, Manzano A, Arenal CC, Olaechea PM, Blanquer J, Reig Valero R, Belenger A, Altaba S, Alvarez-S?nchez B, Alberto Picos S, S?nchez-Miralles A, Bonastre J, Palamo M, Cebrian J, Cu?at J, Romero B, Zaragoza R, Paricio V, Marques A, S?nchez-Morcillo S, Tormo S, Latour J, Angel Garc?a M, Ribas A.
Hospital Joan XXIII, Critical Care Department - IISPV - URV - CIBERES, Tarragona, Spain.
Abstract
Objectives The impact of oseltamivir on mortality in critically ill patients with 2009 pandemic influenza A (2009 H1N1) is not clear. The main objective of this study was to investigate the relationship between the timing of antiviral administration and intensive care unit (ICU) outcomes. Methods Prospective, observational study of a cohort of ICU patients with confirmed 2009 H1N1 infection. Clinical data, treatment and outcome were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 2 days, and patients administered late treatment (LT), initiated after this timepoint. Multivariate analysis and propensity score were used to determine the effect of oseltamivir on ICU mortality. Results Six hundred and fifty-seven patients were enrolled. Four hundred and four (61.5%) patients required mechanical ventilation (MV; mortality 32.6%). Among them, 385 received effective antiviral therapy and were included in the study group. All patients received oseltamivir for a median duration of 10 days (interquartile range 8-14 days). Seventy-nine (20.5%) ET patients were compared with 306 LT patients. The two groups were comparable in terms of main clinical variables. ICU length of stay (22.7 ? 16.7 versus 18.4 ? 14.2 days; P = 0.03), hospital length of stay (34.0 ? 20.3 versus 27.2 ? 18.2 days; P = 0.001) and MV days (17.4 ? 15.2 versus 14.0 ? 12.4; P = 0.04) were higher in the LT group. ICU mortality was also higher in LT (34.3%) than in ET (21.5%; OR = 1.9; 95% CI 1.06-3.41). A multivariate model identified ET (OR = 0.44; 95% CI 0.21-0.87) as an independent variable associated with reduced ICU mortality. These results were confirmed by propensity score analysis (OR = 0.44; 95% CI 0.22-0.90; P < 0.001). Conclusions Our findings suggest that early oseltamivir administration was associated with favourable outcomes among critically ill ventilated patients with 2009 H1N1 virus infection.
PMID: 21385717 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21385717